The purpose of the study is to investigate if rosuvastatin, added on top of all other medicines prescribed to subjects with symptomatic systolic heart failure, reduces the combined endpoint of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke (time to first event)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
5,013
The primary objective of this study is to determine whether rosuvastatin reduces the combined endpoint of cardiovascular death or non-fatal myocardial infarction (MI) or non-fatal stroke (time to first event).
The secondary objectives are to evaluate the effects of rosuvastatin on:
Total mortality
Any coronary event defined as the combined endpoint of sudden death or fatal or non-fatal MI or Percutaneous Transluminal Coronary Angioplasty (PTCA) or Coronary Artery Bypass Grafting (CABG) or defibrillation of ventricular fibrillation by an implant
Cardiovascular mortality with cause-specific mortality for sudden death; fatal MI; and death from worsening heart failure
Total number of hospitalizations for cardiovascular causes; for unstable angina; and for worsening heart failure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Aalst, Belgium
Research Site
Bouge, Belgium
Research Site
Bruges, Belgium
Research Site
Brussels, Belgium
Research Site
Edegem, Belgium
Research Site
Ensival, Belgium
Research Site
Fléron, Belgium
Research Site
Genk, Belgium
Research Site
Huy, Belgium
Research Site
Leuven, Belgium
...and 365 more locations